Skip to Content

Tag: Fisher & Paykel Healthcare


Also Noted

F&P looks to build second campus

September 1, 2022HME News Staff

AUCKLAND, New Zealand – Fisher & Paykel Healthcare has entered into a sale and purchase agreement to acquire a 105-hectare site in Karaka for $275 million to build a second campus in New Zealand. “With our current site nearing capacity, we are pleased to take this step towards securing additional land to enable our continued growth,” said Scott St. John, board chair for Fisher & Paykel Healthcare. “We have consistently signaled the importance of long-term infrastructure planning...

Fisher & Paykel Healthcare


Read Full Articlered right arrow icon

News

In brief: FDA update, F&P prediction, home infusion access

August 26, 2022HME News Staff

WASHINGTON – The U.S. Food and Drug Administration updated its safety communication for the Philips recall this month, saying it received more than 48,000 medical device reports, including 44 reports of death, associated with the foam breakdown or suspected foam breakdown in certain CPAP devices from May 1, 2022, through July 31, 2022.  The agency previously reported in May that it received more than 21,000 MDRs, including 124 reports of death, associated with the foam breakdown...

Fisher & Paykel Healthcare, Home Infusion Therapy, Philips Recall


Read Full Articlered right arrow icon

F&P predicts revenue boost in second half 

Vendors

F&P predicts revenue boost in second half 

August 22, 2022HME News Staff

AUCKLAND, N.Z. – Fisher & Paykel Healthcare expects operating revenue for the first half of the 2023 financial year to be about $670 million and net profit after tax to be about $85 million to $95 million, assuming current exchange rates and a continuation of trading conditions in the first four months.  This would represent an increase in revenue on pre-pandemic levels ($570.9 million in the first half of fiscal year 2020) and a decline in revenue compared to the prior comparable period...

Financial Results, Fisher & Paykel Healthcare


Read Full Articlered right arrow icon

Also Noted

Fisher & Paykel board director to retire

July 6, 2022HME News Staff

AUCKLAND, New Zealand – Fisher & Paykel Healthcare Director Geraldine McBride will retire from the board at the close of the company’s annual shareholders meeting in August. She has served as an independent director on the board since August 2013. “Geraldine has been a valuable presence in the boardroom throughout a period of significant growth for our company,” said Scott St John, board chair. “We have benefited greatly from her experience, drawn from a successful career...

Fisher & Paykel Healthcare


Read Full Articlered right arrow icon

Also Noted

F&P selects Future Director 

May 31, 2022HME News Staff

AUCKLAND, New Zealand – Fisher & Paykel Healthcare has selected Tracey Barron to participate in the Future Directors program starting June 1. Barron has more than 25 years of experience across a broad range of health-related roles, including chief of strategy for Southern Cross Healthcare. “We welcome the perspective and experience Tracey will bring,” said Scott St. John, chairman of the board. “She is a proven executive with a deep understanding of public and private health...

Fisher & Paykel Healthcare, Future Directors


Read Full Articlered right arrow icon

Also Noted

F&P adds professor to board 

May 31, 2022HME News Staff

AUCKLAND, New Zealand – Cather Simpson, a PhD with expertise in lasers and photonics, has been appointed as a non-executive director of Fisher & Paykel Healthcare starting June 1. Simpson is a professor of physics and chemical sciences at the University of Auckland and a partner at Pacific Channel, an early-stage investment company. She is also a director of the International Society for Optics & Photonics (SPIE) and founder/director for Orbis Diagnostics. “We are pleased to announce...

Board of Directors, Cather Simpson, Fisher & Paykel Healthcare


Read Full Articlered right arrow icon

Lewis Gradon

Vendors

F&P’s Homecare group hangs on

May 27, 2022Liz Beaulieu, Editor

AUCKLAND, New Zealand – Fisher & Paykel Healthcare reported steady revenue of $469.5 million for its Homecare product group for its financial year ended March 31, 2022, despite downward pressure from supply chain constraints and the COVID-19 pandemic that have reduced new patient diagnoses and set ups.  The company reported a 1% increase in revenue for the Homecare product group for 2022 compared to the prior year and a 3% increase for OSA masks, specifically.  “That’s...

CPAP, Fisher & Paykel Healthcare, Lewis Gradon, supply chain challenges


Read Full Articlered right arrow icon

Fisher & Paykel Evora Full

Also Noted

F&P’s Evora debuts in US 

April 19, 2022HME News Staff

AUCKLAND, New Zealand – Fisher & Paykel Healthcare has launched its Evora Full, a compact full-face mask for obstructive sleep apnea, in the United States. The mask has received FDA 510(k) clearance, paying the way for its sale in the U.S. in early May, following launches in Australia, New Zealand, Europe and Canada. “We welcome this clearance from the FDA and look forward to offering this unique full-face mask to our customers and patients,” said Justin Callahan, president-North...

CPAP Mask, Evora Full, Fisher & Paykel Healthcare


Read Full Articlered right arrow icon

Lewis Gradon

Vendors

Reporter’s notebook: F&P’s growth and gross margin

December 29, 2021Liz Beaulieu, Editor

AUCKLAND, New Zealand – Fisher & Paykel Healthcare expects to make a $700 million investment in land and buildings over the next five years to accommodate future growth, say company officials.  In November, the company was “making good progress” on its third manufacturing facility in Mexico and “earthworks were underway” on its fifth building site in Auckland, said CEO Lewis Gradon.  “Once that fifth building site is complete, our current site here...

Fisher & Paykel Healthcare, Lewis Gradon


Read Full Articlered right arrow icon

F&P: It could be ‘long journey with COVID-19’

Vendors

F&P: It could be ‘long journey with COVID-19’

December 3, 2021Liz Beaulieu, Editor

AUCKLAND, New Zealand – Fisher & Paykel Healthcare expects new patient diagnoses for sleep therapy in the second half of its 2022 fiscal year to be at or above the previous year, but there is “uncertainty” with another uptick in the number of COVID-19 cases.  The company reported revenue of $227 million for the first half of the year for its home care products group, which includes products used to treat obstructive sleep apnea, representing only a 0.3% increase.  "Growth...

CPAP, Fisher & Paykel Healthcare


Read Full Articlered right arrow icon